Global Pharma: The Shell Game Continues
This isn't a bug; it's a feature of the international pharmaceutical pricing model, cleverly designed to externalize costs and maximize profits. FIRST INSTANCE: The 'Price Elasticity' Gambit (c. 1990s) The pharmaceutical industry's strategy of differential pricing for the same drug across countries solidified in the late 20th century. Facing increasing price controls and public health systems in
Europe, and a largely unregulated US market, companies began treating the US as a 'profit center.' This meant higher prices in America subsidized lower prices (or R&D, as they'd claim) elsewhere. This dynamic was well-established by 1993, when pharmaceutical companies engaged in significant lobbying to fend off Clinton's healthcare reform efforts, successfully preserving a pricing environment that
allowed this kind of arbitrage (Public Citizen, 1993). REPETITIONS: Whack-A-Mole for 'Savings' (Early 2000s - Present) Every attempt by a major market to drive down drug costs has been met with a shift in pricing. When Canada notably began allowing parallel imports and negotiated prices for specifics drugs, US companies often responded by either threatening to limit supply to Canada or by subtly
increasing prices for other, non-negotiated drugs in that market, or simply pushing costs more aggressively into the US. For example, during the push for Medicare Part D in 2003, pharmaceutical lobbyists successfully blocked government negotiation of drug prices, ensuring US consumers continued to pay top dollar, effectively insulating global profits from foreign price controls (Kaiser Family